CompletedNCT04306146
Official study titleA Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects on Neurophysiological Biomarkers of CAD-9303 Oral Treatment in Subjects With Schizophrenia and Normal Healthy Volunteers
This study has finished and is no longer accepting participants.
Multiple locations, including Long BeachSchizophreniaMedication studyAges 18–50
- Countries
- United States
- Sponsor
- Cadent Therapeutics
CompletedNCT03751280
Official study titleA Randomized, Sham-Controlled Study of PEAR-004 as an Adjunct to Standard-of-care Treatment for Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Garden GroveSchizophreniaDevice studyAges 18–65
- Countries
- United States
- Sponsor
- Novartis Pharmaceuticals
CompletedNCT03064776
Official study titlePilot Study of m-RESIST, an m-Health Program for Treatment-resistant Schizophrenia: Acceptability, Usability, Satisfaction and Perceived Quality of Life Reported by Patients and Caregivers
This study has finished and is no longer accepting participants.
Multiple locations, including BudapestSchizophreniaDevice studyAges 18–45
- Countries
- Hungary, Israel, Spain
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
CompletedNCT02897167
Official study titleRetrospective and Prospective Study of the Activation of Proinflammatory Pathways of Toll-like Receptors in Patients With Schizophrenia: a Comparative Effect of Risperidone vs Aripiprazole
This study has finished and is no longer accepting participants.
In SantanderSchizophreniaObservational studyAges 15–50
- Countries
- Spain
- Sponsor
- Fundación Marques de Valdecilla
Active Not RecruitingNCT06105151
Official study titleA Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Food Effects of a Single Oral VV119 Capsule in Healthy Chinese Volunteers
This study is no longer accepting new participants.
In BeijingSchizophreniaMedication studyAges 18–60
- Countries
- China
- Sponsor
- Vigonvita Life Sciences
CompletedNCT02248987
This study has finished and is no longer accepting participants.
In SeoulSchizophreniaObservational studyAges 20–55
- Countries
- South Korea
- Sponsor
- Seoul National University Hospital
CompletedNCT03379480
Official study titleExamination of Therapeutic Efficacy and Potential Mechanisms of Yoga Treatment in Schizophrenia
This study has finished and is no longer accepting participants.
In BangaloreSchizophreniaBehavioural studyAges 18–45
- Countries
- India
- Sponsor
- National Institute of Mental Health and Neuro Sciences, India
TerminatedNCT00669903
What is this study about?This study evaluates the safety of AZD0328 for people with schizophrenia.
This study ended early.
Multiple locations, including Garden GroveSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- AstraZeneca
CompletedNCT02876900
Official study titleA Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week, In-Patient Study to Assess Efficacy and Safety of HP-3070 in Subjects Diagnosed With Schizophrenia
This study has finished and is no longer accepting participants.
In Jersey CitySchizophreniaMedication studyAges 18+
- Countries
- United States
- Sponsor
- Noven Pharmaceuticals, Inc.
CompletedNCT03150771
What is this study about?This study evaluated the safety of Aripiprazole for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–64
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
CompletedNCT04461119
What is this study about?Researchers compared Evenamide and placebo, tracking side effects to assess safety and tolerability in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including GlendaleSchizophreniaMedication studyAges 18+
- Countries
- United States, India
- Sponsor
- Newron Pharmaceuticals SPA
CompletedNCT00535132
About this title
Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone
Read the official source — NCT00535132Official study titleA Blinded-initiation Study of Medication Satisfaction in Subjects With Schizophrenia Treated With Paliperidone ER After Suboptimal Response to Oral Risperidone
This study has finished and is no longer accepting participants.
Multiple locations, including CerritosSchizophreniaMedication studyAges 18+
- Countries
- United States, Argentina, Colombia, + 3 others
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.